newdrugapprovals.org
New “mTOR” inhibitor from Exelixis, Inc., XL 388
XL 388 A Novel Class of Highly Potent, Selective, ATP-Competitive, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin (mTOR) Benzoxazepine-Containing Kinase Inhibitor [7-(6-Am…